Overall Status

Active, not recruiting (2)

Recruiting (1)

Phase

early phase 1 (1)

phase 1 (1)

phase 2 (1)

Sponsor

National Cancer Institute (NCI) (2)

M.D. Anderson Cancer Center (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

atezolizumab (1)

cabozantinib s-malate (1)

durvalumab (1)

eribulin mesylate (1)

ipilimumab (1)

laboratory biomarker analysis (1)

nivolumab (1)

therapeutic conventional surgery (1)

tremelimumab (1)

Study Documents

Intervention Type

biological (2)

drug (2)

other (1)

procedure (1)

Funder Type

NIH (2)

Other (1)

Study Type

Interventional (3)

stage iii renal pelvis cancer ajcc v7

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Advanced Clear Cell Renal Cell Carcinoma, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Bladder

Active, not recruiting

Advanced Clear Cell Renal Cell Carcinoma
+35 more

Cabozantinib S-malate
+2 more

Duarte, California
+7 more

Jan 3, 2023

Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma,

Active, not recruiting

Hydronephrosis
+18 more

Durvalumab
+2 more

Houston, Texas

M D Anderson Cancer Center

Oct 31, 2022

Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral

Recruiting

Locally Advanced Renal Pelvis Urothelial Carcinoma
+20 more

Atezolizumab
+2 more

Duarte, California
+16 more

Aug 10, 2022